### North America Structured Investments

# 5yrNC1yr Auto Callable Review Notes linked to the MerQube US Large-Cap Vol Advantage Index

The following is a summary of the terms of the notes offered by the preliminary pricing supplement hyperlinked below. Index Overview

The MerQube US Large-Cap Vol Advantage Index (the "Index") attempts to provide a dynamic rules-based exposure to an unfunded rolling position in E-Mini® S&P 500® futures (the "Futures Contracts"), which reference the S&P 500® Index (the "Constituent"), while targeting a level of implied volatility, with a maximum exposure to the Futures Contracts of 500% and a minimum exposure to the Futures Contracts of 09%. The Index is subject to a 6.0% per annum daily deduction. The Constituent consists of stocks of 500 companies selected to provide a performance benchmark for the U.S. equity markets.

## Summary of Terms

Issuer: JPMorgan Chase Financial Company LLC

JPMorgan Chase & Co. Guarantor:

Minimum Denomination:

The MerQube US Large-Cap Vol Advantage Index (Bloomberg ticker; MQUSLVA). The level of the Index Index (Index Ticker):

reflects a deduction of 6.0% per annum that accrues daily.

Pricing Date: September 16, 2024 Final Review Date: September 17, 2029 Maturity Date: September 20, 2029

Review Dates: Quarterly (after an initial one-year non-call period)

With respect to the first through sixteenth Review Dates: 100.00% of the Initial Value; with respect to the final Call Value:

Review Date: 50.00% of the Initial Value

Barrier Amount: 50,00% of the Initial Value

CUSIP: 48135TU43

Preliminary

Pricing Supplement: http://sp.jpmorgan.com/document/cusip/48135TU43/doctype/Product\_Termsheet/document.pdf

Estimated Value: The estimated value of the notes, when the terms of the notes are set, will not be less than \$870.00 per \$1,000

principal amount note. For information about the estimated value of the notes, which likely will be lower than the price you paid for the notes, please see the hyperlink above.

You may lose some or all of your principal at maturity. Any payment on the notes is subject to the credit risk of JPMorgan Chase Financial Company LLC, as issuer of the notes and the credit risk of JPMorgan Chase & Co., as guarantor of the notes.

#### Automatic Call

If the closing level of the Index on any Review Date is greater than or equal to the applicable Call Value, the notes will be automatically called for a cash payment, for each \$1,000 principal amount note, equal to (a) \$1,000 plus (b) the Call Premium Amount applicable to that Review Date, payable on the applicable Call Settlement Date. No further payments will be made on the notes.

Review Date	Call Premium*	Review Date	Call Premium*
First	At least 13.500%	Tenth	At least 43.875%
Second	At least 16.875%	Eleventh	At least 47.250%
Third	At least 20.250%	Twelfth	At least 50.625%
Fourth	At least 23.625%	Thirteenth	At least 54.000%
Fifth	At least 27,000%	Fourteenth	At least 57.375%
Sixth	At least 30.375%	Fifteenth	At least 60.750%
Seventh	At least 33.750%	Sixteenth	At least 64.125%
Eighth	At least 37.125%	Final	At least 67.500%
Ninth	At least 40 500%		

### Payment at Maturity

If the notes have not been automatically called (and therefore the Final Value is less than the Barrier Amount), your payment at maturity per \$1,000 principal amount note will be calculated as follows:

\$1,000 + (\$1,000 × Index Return)

If the notes have not been automatically called (and therefore the Final Value is less than the Barrier Amount), you will lose more than 50.00% of your principal amount at maturity and could lose all of your principal amount at maturity.

Investing in the notes linked to the index involves a number of risks. See "Selected Risks" on page 2 of this document, "Risk Factors" in the prospectus supplement and the relevant product supplement and underlying supplement, Annex A to the prospectus addendum and "Selected Risk Continued and the relevant pricing supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this document or the relevant product supplement, underlying supplement, the prospectus supplement, prospectus and prospectus addendum. Any representation to the contrary is a criminal offernional defendence.

Hypothetical Amount Payable**					
Index Return at Review Date	Total Return at First Review Date	Total Return at Sixth Review Date	Total Return at Twelfth Review Date	Total Return at Final Review Date	
100.00%	13.50%	30.375%	50.625%	67.50%	
80.00%	13.50%	30.375%	50.625%	67.50%	
40.00%	13,50%	30.375%	50.625%	67.50%	
20.00%	13.50%	30.375%	50.625%	67.50%	
10.00%	13.50%	30.375%	50.625%	67.50%	
0.00%	13,50%	30.375%	50.625%	67.50%	
-5.00%	N/A	N/A	N/A	67.50%	
-10.00%	N/A	N/A	N/A	67.50%	
-20.00%	N/A	N/A	N/A	67.50%	
-40.00%	N/A	N/A	N/A	67.50%	
-50.00%	N/A	N/A	N/A	67.50%	
-50.01%	N/A	N/A	N/A	-50.01%	
-60.00%	N/A	N/A	N/A	-60.00%	
-80.00%	N/A	N/A	N/A	-80.00%	
-100.00%	N/A	N/A	N/A	-100.00%	

<sup>\*</sup> In each case, to be determined on the Pricing Date, but not less than the applicable minimum Call Premium.

The "total return" as used above is the number expressed as a percentage, that results from comparing the payment on the applicable payment date per \$1,000 principal amount note to

The hypothetical returns on the notes shown above apply only if you hold the notes for their entire term or until automatically called. These hypotheticals do not reflect fees or expenses that would be associated with any sale in the secondary market. If these fees and expenses were included, the hypothetical returns shown above would likely be lower.

Capitalized terms used but not defined herein shall have the meaning set forth in the preliminary pricing supplement.

<sup>&</sup>quot; Not all Review Dates reflected. Reflects a Call Premium of 13.50% per annum. The Call Premium will be determined on the Pricing Date and will not be less than 13.50% per annum.



# 5yrNC1yr Auto Callable Review Notes linked to the MerQube US Large-Cap Vol Advantage Index

#### Selected Risks

#### Risks Relating to the Notes Generally

- Your investment in the notes may result in a loss. The notes do not guarantee any return of principal.
- The level of the Index will include a 6.0% per annum daily deduction.
- Any payment on the notes is subject to the credit risks of JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. Therefore the value of the notes prior to maturity will be subject to changes in the market's view of the creditworthiness of JPMorgan Chase Financial Company LLC or JPMorgan Chase & Co.
- As a finance subsidiary, JPMorgan Chase Financial Company LLC has no independent operations and has limited assets,
- The appreciation potential of the notes is limited to any Call Premium Amount paid on the notes.
- The benefit provided by the Barrier Amount may terminate on the final Review Date.
- · The automatic call feature may force a potential early exit.
- · No interest payments, dividend payments or voting rights.
- Lack of liquidity: J.P. Morgan Securities LLC (who we refer to as "JPMS") intends to offer to purchase the
  notes in the secondary market but is not required to do so. The price, if any, at which JPMS will be willing to
  purchase notes from you in the secondary market, if at all, may result in a significant loss of your principal.
- The tax consequences of the notes may be uncertain. You should consult your tax adviser regarding the U.S. federal income tax consequences of an investment in the notes.

#### Risks Relating to Conflicts of Interest

- Potential conflicts: We and our affiliates play a variety of roles in connection with the issuance of notes, including acting as calculation agent and hedging our obligations under the notes, and making the assumptions used to determine the pricing of the notes and the estimated value of the notes when the terms of the notes are set. It is possible that such hedging or other trading activities of J.P. Morgan or its affiliates could result in substantial returns for J.P. Morgan and its affiliates while the value of the notes declines.
- Our affiliate, JPMS, worked with MerQube in developing the guidelines and policies governing the composition and calculation of the Index.

# Selected Risks (continued)

#### Risks Relating to the Estimated Value and Secondary Market Prices of the Notes

- The estimated value of the notes will be lower than the original issue price (price to public) of the notes.
- The estimated value of the notes does not represent future values and may differ from others' estimates.
- The estimated value of the notes is determined by reference to an internal funding rate
- The value of the notes, which may be reflected in customer account statements, may be higher than the
  then current estimated value of the notes for a limited time period.

#### Risks Relating to the Index

- The Index may not be successful or outperform any alternative strategy.
- The Index may not approximate its target volatility.
- The Index is subject to risks associated with the use of significant leverage.
- The Index may be significantly uninvested.
- The Index may be adversely affected if later futures contracts have higher prices than an expiring futures
  contract included in the Index.
- The Index is an excess return index that does not reflect "total returns."
- JPMorgan Chase & Co. is currently one of the companies that make up the S&P 500<sup>®</sup> Index.
- Concentration risks associated with the Index may adversely affect the value of your notes.
- . The Index is subject to significant risks associated with futures contracts, including volatility.
- Suspension or disruptions of market trading in futures contracts may adversely affect the value of your notes.
- The official settlement price and intraday trading prices of the relevant futures contracts may not be readily available.
- Changes in the margin requirements for the futures contracts included in the Index may adversely affect the value of the notes.
  - The Index was established on February 11, 2022 and may perform in unanticipated ways.

The risks identified above are not exhaustive. Please see "Risk Factors" in the prospectus supplement and the applicable product supplement and underlying supplement, Annex A to the prospectus addendum and "Selected Risk Considerations" in the applicable preliminary pricing supplement for additional information.

# Additional Information

Any information relating to performance contained in these materials is illustrative and no assurance is given that any indicative returns, performance or results, whether historical or hypothetical, will be achieved. These terms are subject to change, and J.P. Morgan undertakes no duty to update this information. This document shall be amended, superseded and replaced in its entirety by a subsequent preliminary pricing supplement and/or pricing supplement, and the documents referred to therein. In the event any inconsistency between the information presented herein and any such preliminary pricing supplement and/or pricing supplement shall govern.

Past performance, and especially hypothetical back-tested performance, is not indicative of future results. Actual performance may vary significantly from past performance or any hypothetical back-tested performance. This type of information has inherent limitations and you should carefully consider these limitations before placing reliance on such information.

IRS Circular 230 Disclosure: JPMorgan Chase & Co. and its affiliates do not provide tax advice, Accordingly, any discussion of U.S. tax matters contained herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone unaffiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.

Investment suitability must be determined individually for each investor, and the financial instruments described herein may not be suitable for all investors. This information is not intended to provide and should not be relied upon as providing accounting, legal, regulatory or tax advice. Investors should consult with their own advisers as to these matters.

This material is not a product of J.P. Morgan Research Departments.